Bavarian Nordic

@BavarianNordic

Biopharmaceutical company developing cancer immunotherapies and vaccines against infectious diseases. OMX:$BAVA, OTC:$BVNRY

Vrijeme pridruživanja: kolovoz 2011.

Tweetovi

Blokirali ste korisnika/cu @BavarianNordic

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @BavarianNordic

  1. 17. pro 2019.

    Bavarian Nordic announces the sale of Priority Review Voucher

    Poništi
  2. proslijedio/la je Tweet

    In support of & its mission to help protect the health and wellbeing of its population, announced it will provide up to 200,000 courses of ’s investigational Ebola vaccine regimen for use in Rwanda. Learn more:

    Poništi
  3. 22. stu 2019.

    We are excited to be at . Yesterday's poster session featured a presentation on our work in and by Professor Jack Stapleton from

    Poništi
  4. proslijedio/la je Tweet
    14. stu 2019.

    Muliirwa Mulire was the first patient to receive the first dose of the Ad26.ZEBOV/MVA-BN-Filo vaccine today in Goma, DRC. In total, vaccinated 40 participants🙌 📸Credit: Yves Ndjadi LOPONGO@MSF |

    , , i još njih 6
    Poništi
  5. 14. stu 2019.

    thanks and HHS ASPR for their global leadership in and . Through our 15 year partnership we now have an FDA approved vaccine to protect all Americans.

    Poništi
  6. proslijedio/la je Tweet
    13. stu 2019.

    New Quick Take video: A New Vaccine against Smallpox. See all Quick Take videos:

    Poništi
  7. 13. stu 2019.

    Phase 3 Results of Bavarian Nordic’s Vaccine Published in

    Poništi
  8. 12. stu 2019.

    Bavarian Nordic appoints Jean-Christophe May as Executive Vice President and Chief Commercial Officer

    Poništi
  9. proslijedio/la je Tweet

    Following years of research in collaboration with global partners, Johnson & Johnson is proud to announce submission of license applications from for its investigational Ebola vaccine regimen to the European Medicines Agency.

    Poništi
  10. 7. stu 2019.

    Congratulations to our partner on the filing for European approval of the vaccine!

    Poništi
  11. 6. stu 2019.

    Our 2019 third quarter results are published. We remain on track to meet full year guidance. Conference call today at 2:00 pm CET

    Poništi
  12. 5. stu 2019.

    Day 2 at - come visit us at booth 121G74 and discuss your live vaccine project with us. The complex made simple:

    Poništi
  13. 31. lis 2019.

    We applaud our partner for their commitment to fighting and their donation of up to 500,000 doses of the investigational vaccine regimen to the Democratic Republic of Congo.

    Poništi
  14. 21. lis 2019.

    Strong cash flow generation allows us to continue progressing our promising innovative pipeline

    Prikaži ovu nit
    Poništi
  15. 21. lis 2019.

    Exploits significant manufacturing synergies and builds on our expertise

    Prikaži ovu nit
    Poništi
  16. 21. lis 2019.

    Accelerates our vision by 3 years to become a leading and profitable vaccine company

    Prikaži ovu nit
    Poništi
  17. 21. lis 2019.

    Acquisition of Rabipur/RabAvert and Encepur which have strong positions in attractive markets

    Prikaži ovu nit
    Poništi
  18. 21. lis 2019.

    Bavarian Nordic to acquire the manufacturing and global rights to rabies and TBE vaccines from GlaxoSmithKline.

    Prikaži ovu nit
    Poništi
  19. 17. lis 2019.

    Thank you for meeting with yesterday to discuss biosecurity at and . Your leadership and support ensures the U.S.’s public health preparedness remains a priority

    Poništi
  20. 17. lis 2019.

    Thank you for meeting with yesterday to discuss biosecurity at and . Your leadership and support ensures the U.S.’s public health preparedness remains a priority

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·